Anonymous
Guest
Anonymous
Guest
Check out the Inventiv website. Our jobs selling both Xarelto and Invokana in our current territories have been posted. How kind of them! Good luck everyone!
Check out the Inventiv website. Our jobs selling both Xarelto and Invokana in our current territories have been posted. How kind of them! Good luck everyone!
Inventive will be greatly challenged to find enough qualified reps to fill this. As a company they are a huge step down from Quintiles in training, quality to the client, and employee benefits.
My thought is that this is a knee jerk reaction by Janssen when getting a therapeutic competitor. You never know what they are thinking but the tired overused play book is the " share of voice" model. Flood the market with reps, throw 'em up " against the wall." See what sticks. Not too bright, but hey, it's their money. It's obvious, from the beginning, that Janssen gets "A for effort" but doesn't totally know what it's doing in the diabetes market. They're lucky, right now that AZ is distracted by the Pfizer buy out. I think 6767 is safe until Dec. ( which was the length of the contract) Q's performance and delivery on this contract has been excellent, but who really knows? No one at Q, certainly no one at Janssen. I've seen a lot of stupid things happen in this industry. The old Glengarry Glenross motto:" always be closing" is, in today's pharma "always be looking."